SecBot SecBot
3 ·Filed Apr 30, 2026

COAG

Hemab Therapeutics Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-198220
Form 3, initial insider ownership statement
Actionable Insight • Neutral

This is a routine Form 3 filing with no actionable trading signal. Monitor future Form 4 filings for any insider transactions that may indicate conviction or changes in outlook.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.00
T+0 close · Apr 30, 2026 · via day close
Latest settled
+39.00%
T+60 · $47.26
Vs SPY
+35.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $34.00entry
  2. T+1 · 7mo ago −25.47%α −25.13% · $25.34
  3. T+5 · 6mo ago −26.12%α −28.46% · $25.12
  4. T+20 · 6mo ago −20.21%α −25.47% · $27.13
  5. T+60 · 4mo ago +39.00%α +35.93% · $47.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

John Michael Maraganore filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his holdings in Hemab Therapeutics Holdings, Inc. (COAG). This is a routine filing required upon becoming an insider and contains no material financial information or trading activity.

Key Facts

  • John Michael Maraganore filed Form 3 on April 30, 2026, disclosing beneficial ownership of Hemab Therapeutics Holdings, Inc. (COAG).
  • Holdings include 17,974 shares of common stock (indirect), Series B and Series C Preferred Stock convertible into common stock, and warrants to purchase common stock at exercise prices of $2.16, $7.07, and $6.00 per share.
  • The filing is a standard initial ownership report required under Section 16(a) of the Exchange Act, with no trading activity or material corporate event.

Financial Impact

No financial impact, filing is a routine insider ownership disclosure with no transaction or material change.

Risk Factors

  • No material risks identified from this filing alone.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-198220
Document: 0001193125-26-198220-index-headers.html0001193125-26-198220
Document: 0001193125-26-198220-index.html0001193125-26-198220
Document: 0001193125-26-198220.txt0001193125-26-198220

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026